Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

9.3% of U.S. cancer survivors are current smokers, shows study

Nine years after diagnosis, 9.3 percent of U.S. cancer survivors were current smokers and 83 percent of these individuals were daily smokers who averaged 14.7 cigarettes per day, according to a report in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research (AACR).

6 Aug 2014

New guideline recommends genetic testing of tumors for colorectal cancer patients

Of the 143,000 patients diagnosed with colorectal cancer annually in the U.S., up to 25 percent have a familial risk of colorectal cancer. A new guideline from the U.S. Multi-Society Task Force on Colorectal Cancer recommends genetic testing of tumors for all newly diagnosed colorectal cancer patients.

5 Aug 2014

Repurposed drug used to treat ovarian cancer gives positive results

A repurposed drug originally used to treat ovarian cancer saw positive results for patients with advanced peritoneal cancers during a phase I clinical trial at The University of Kansas Cancer Center.

5 Aug 2014

EMD Serono begins MSB0010718C Phase II study in mMCC patients

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the initiation of an international Phase II study designed to assess the efficacy and safety of MSB0010718C, an investigational fully human IgG1 monoclonal antibody that binds to programmed death-ligand 1 (PD-L1).

29 Jul 2014

Viewpoints: GOP's 'political sideshow;' Boehner says House must defend the constitution; Jonathan Gruber on center stage about subsidies

This week, before the House leaves for its August recess, the GOP majority is expected to approve a lawsuit against Obama.

29 Jul 2014

CanTx, Novogen name two key CMOs to manufacture clinical batches of anti-cancer drug Cantrixil

Oncology drug developer, CanTx Inc., and its parent company, Novogen Ltd., today announced that they have named two key contract manufacturing organizations (CMOs) to produce clinical batches of the experimental anti-cancer drug, Cantrixil.

26 Jul 2014

Study confirms effectiveness of EKF PointMan technology for isolating low-level DNA mutations in blood

EKF, announces that the latest results from its collaboration with the Institute of Life Sciences at the University of Swansea, UK.

From EKF Diagnostics 22 Jul 2014

CFDA approves CASI's ENMD-2076 Phase II trial in triple-negative breast cancer patients

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that China's Food and Drug Administration has approved the Company's application to conduct a Phase II clinical trial in triple-negative breast cancer (TNBC) patients in China for its proprietary drug candidate, ENMD-2076.

21 Jul 2014

Engineering single-celled parasite in cat's intestine as cancer vaccine

Toxoplasma gondii (T. gondii) is a single-celled parasite that is happiest in a cat's intestines, but it can live in any warm blooded animal. Found worldwide, T. gondii affects about one-third of the world's population, 60 million of which are Americans.

16 Jul 2014

New potential avenues to predict and prevent ovarian cancer metastasis

Circulating tumor cells spread ovarian cancer through the bloodstream, homing in on a sheath of abdominal fatty tissue where it can grow and metastasize to other organs, scientists at The University of Texas MD Anderson Cancer Center report in Cancer Cell.

15 Jul 2014

Researchers describe innovative technique for early disease detection

Despite impressive medical strides, cancer remains a leading killer and overwhelming burden to healthcare systems, causing well over a half million fatalities per year with a projected cost of $174 billion by 2020, according to the National Cancer Institute.

15 Jul 2014

CASI's ENMD-2076 gets FDA Orphan Drug designation for HCC treatment

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that its orally-active, Aurora A/angiogenic kinase inhibitor, ENMD-2076, has received Orphan Drug designation from the U.S. Food and Drug Administration for the treatment of hepatocellular carcinoma (HCC).

7 Jul 2014

Video interview highlights latest research developments in women’s reproductive health using Chromatrap solid state ChIP assay

An informative video interview with Professor Steve Conlan of the College of Medicine at Swansea University (UK) highlights the latest research developments in women’s reproductive health using unique molecular biology tools.

From Chromatrap® - Porvair Sciences Ltd 30 Jun 2014

FAK inhibitors prevent ovarian cancer progression

A team of scientists, led by principal investigator David D. Schlaepfer, PhD, professor in the Department of Reproductive Medicine at the University of California, San Diego School of Medicine report that small molecule inhibitors to a protein called focal adhesion kinase (FAK) selectively prevent the growth of ovarian cancer cells as tumor spheroids.

20 Jun 2014

New treatment for ovarian cancer can improve response rates

Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong the time until cancers recur.

20 Jun 2014

Novogen, CanTx believe Intra-Peritoneal Trx-1 could be utilized as first-line therapy for ovarian cancer

Australian oncology drug development company Novogen Limited and CanTx Inc., its joint venture with Yale University, today announced the success of proof-of-concept pre-clinical studies confirming the potency of experimental drug, Trx-1, in the treatment of primary ovarian cancer when delivered into the peritoneal cavity.

18 Jun 2014

Researchers discover that genetic pathway could slow spread of ovarian cancer

University of Adelaide research into the origins of ovarian cancer has led to the discovery of a genetic pathway that could slow the spread of the cancer.

18 Jun 2014

New framework for monitoring oral cancer development, progression, recurrence

Each year, approximately 22,000 Americans are diagnosed with oral cancer. The five-year survival rate of 40% in the U.S. is one of the lowest of the major cancers, and it has not improved in the past 40 years.

11 Jun 2014

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering microRNA-based Replacement Therapy to treat cancer, today announced the enrollment of the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34, the company's lead product candidate and first microRNA mimic in human clinical trials in oncology.

11 Jun 2014

Northwest Biotherapeutics initiates Phase III trial of DCVax-L in Germany

Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announced today that it has initiated the Phase III trial of DCVax-L in Germany.

10 Jun 2014

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

9.3% of U.S. cancer survivors are current smokers, shows study

New guideline recommends genetic testing of tumors for colorectal cancer patients

Repurposed drug used to treat ovarian cancer gives positive results

EMD Serono begins MSB0010718C Phase II study in mMCC patients

Viewpoints: GOP's 'political sideshow;' Boehner says House must defend the constitution; Jonathan Gruber on center stage about subsidies

CanTx, Novogen name two key CMOs to manufacture clinical batches of anti-cancer drug Cantrixil

Study confirms effectiveness of EKF PointMan technology for isolating low-level DNA mutations in blood

CFDA approves CASI's ENMD-2076 Phase II trial in triple-negative breast cancer patients

Engineering single-celled parasite in cat's intestine as cancer vaccine

New potential avenues to predict and prevent ovarian cancer metastasis

Researchers describe innovative technique for early disease detection

CASI's ENMD-2076 gets FDA Orphan Drug designation for HCC treatment

Video interview highlights latest research developments in women’s reproductive health using Chromatrap solid state ChIP assay

FAK inhibitors prevent ovarian cancer progression

New treatment for ovarian cancer can improve response rates

Novogen, CanTx believe Intra-Peritoneal Trx-1 could be utilized as first-line therapy for ovarian cancer

Researchers discover that genetic pathway could slow spread of ovarian cancer

New framework for monitoring oral cancer development, progression, recurrence

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Northwest Biotherapeutics initiates Phase III trial of DCVax-L in Germany

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in